USPTO Grants Alterity New Composition of Matter Patent - BioTuesdays

Alterity strengthens IP with new US patent for ATH434 ahead of Phase III MSA trial

Titled “Crystalline Form, and Process for its Production”, the patent was granted by the USPTO. ... The post Alterity strengthens IP with new US patent for ATH434 ahead of Phase III MSA trial appeared first on Stockhead.

IP-intensive industries provide better paying jobs, employ one-third of total workforce, and account for 44% of U.S. gross domestic product: New USPTO study

Press Release IP-intensive industries provide better paying jobs, employ one-third of total workforce, and account for 44% of U.S. gross domestic product: new USPTO study New report offers insight into the economic contributions of industries that p…

USPTO grants Alterity new composition of matter patent - BioTuesdays

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) has announced that the United States Patent and Trademark Office (USPTO) has granted a new composition of matter patent for the company’s lead clinical asset, ATH434, an oral agent designed to treat the underlying pathology of neurodegenerative diseases such as multiple system atrophy (MSA), Parkinson’s disease, and related disorders. According to Alterity, the newly granted patent represents a sign…

Alterity Therapeutics Announces Granting of New U.S. Composition of Matter Patent for ATH434